Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis
Therapeutic drug monitoring (TDM) of methotrexate (MTX), an anticancer drug, is critical since MTX therapy can lead to severe adverse effects if not monitored to ensure clearance. Discriminating and quantifying MTX among its metabolites is challenging, time consuming, and not universally available....
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Biosensors and Bioelectronics: X |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590137023000791 |
| _version_ | 1797733922883239936 |
|---|---|
| author | Gohar Soufi Elodie Dumont Yaman Göksel Roman Slipets Raheel Altaf Raja Kjeld Schmiegelow Habib Bagheri Anja Boisen Kinga Zor |
| author_facet | Gohar Soufi Elodie Dumont Yaman Göksel Roman Slipets Raheel Altaf Raja Kjeld Schmiegelow Habib Bagheri Anja Boisen Kinga Zor |
| author_sort | Gohar Soufi |
| collection | DOAJ |
| description | Therapeutic drug monitoring (TDM) of methotrexate (MTX), an anticancer drug, is critical since MTX therapy can lead to severe adverse effects if not monitored to ensure clearance. Discriminating and quantifying MTX among its metabolites is challenging, time consuming, and not universally available. Therefore, we propose a surface-enhanced Raman scattering (SERS) based method as a rapid and easy-to-use alternative to complex standard methods. We implemented a solid phase extraction (SPE) process in a syringe filter holder (μ-SPE-SFH), suitable for the extraction of MTX and compatible with nanopillar assisted separation (NPAS) and SERS-based detection. All of the parameters related to the extraction, desorption, and NPAS procedure were investigated and optimized. The SERS spectra from maps were analyzed with partial least squares as regression (PLSR) and as a discrimination analysis (PLS-DA) to enable, for the first time with SERS, the identification and quantification of MTX in the presence of its metabolites (7-hydroxy-methotrexate (7-OH MTX) and 2,4-diamino-N(10)-methylpteroic acid (DAMPA)). PLSR facilitated MTX quantification in patient samples in the presence of drugs that could be co-administered during MTX therapy. We found the detection limit to be 0.15 μM while the limit of quantification was 0.55 μM. In addition, for the PLSR, the accuracy, precision, analytical sensitivity, and inverse of analytical sensitivity were 0.66 μM, 0.5 μM, 10.5 μM−1, and 0.1 μM respectively. Furthermore, when quantifying MTX from patient samples, we found a good agreement between calculated MTX concentration with the developed method and reference assay, showing the potential of the sensor in clinical application. |
| first_indexed | 2024-03-12T12:35:44Z |
| format | Article |
| id | doaj.art-dda349d3c7b14579a230acd9bfc8af3a |
| institution | Directory Open Access Journal |
| issn | 2590-1370 |
| language | English |
| last_indexed | 2024-03-12T12:35:44Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biosensors and Bioelectronics: X |
| spelling | doaj.art-dda349d3c7b14579a230acd9bfc8af3a2023-08-29T04:17:57ZengElsevierBiosensors and Bioelectronics: X2590-13702023-09-0114100382Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysisGohar Soufi0Elodie Dumont1Yaman Göksel2Roman Slipets3Raheel Altaf Raja4Kjeld Schmiegelow5Habib Bagheri6Anja Boisen7Kinga Zor8Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, Denmark; Department of Chemistry, Sharif University of Technology, P.O. Box 11365-9516, Tehran, Iran; Corresponding author. Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark.Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, DenmarkCenter for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, DenmarkCenter for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, DenmarkDepartment of Paediatrics and Adolescent Medicine, Rigshospitalet University Hospital, Copenhagen, 2100, Denmark; Denmark and Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, DenmarkDepartment of Paediatrics and Adolescent Medicine, Rigshospitalet University Hospital, Copenhagen, 2100, Denmark; Denmark and Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, DenmarkDepartment of Chemistry, Sharif University of Technology, P.O. Box 11365-9516, Tehran, IranCenter for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, DenmarkCenter for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark; BioInnovation Institute Foundation, Copenhagen N, 2200, DenmarkTherapeutic drug monitoring (TDM) of methotrexate (MTX), an anticancer drug, is critical since MTX therapy can lead to severe adverse effects if not monitored to ensure clearance. Discriminating and quantifying MTX among its metabolites is challenging, time consuming, and not universally available. Therefore, we propose a surface-enhanced Raman scattering (SERS) based method as a rapid and easy-to-use alternative to complex standard methods. We implemented a solid phase extraction (SPE) process in a syringe filter holder (μ-SPE-SFH), suitable for the extraction of MTX and compatible with nanopillar assisted separation (NPAS) and SERS-based detection. All of the parameters related to the extraction, desorption, and NPAS procedure were investigated and optimized. The SERS spectra from maps were analyzed with partial least squares as regression (PLSR) and as a discrimination analysis (PLS-DA) to enable, for the first time with SERS, the identification and quantification of MTX in the presence of its metabolites (7-hydroxy-methotrexate (7-OH MTX) and 2,4-diamino-N(10)-methylpteroic acid (DAMPA)). PLSR facilitated MTX quantification in patient samples in the presence of drugs that could be co-administered during MTX therapy. We found the detection limit to be 0.15 μM while the limit of quantification was 0.55 μM. In addition, for the PLSR, the accuracy, precision, analytical sensitivity, and inverse of analytical sensitivity were 0.66 μM, 0.5 μM, 10.5 μM−1, and 0.1 μM respectively. Furthermore, when quantifying MTX from patient samples, we found a good agreement between calculated MTX concentration with the developed method and reference assay, showing the potential of the sensor in clinical application.http://www.sciencedirect.com/science/article/pii/S2590137023000791 |
| spellingShingle | Gohar Soufi Elodie Dumont Yaman Göksel Roman Slipets Raheel Altaf Raja Kjeld Schmiegelow Habib Bagheri Anja Boisen Kinga Zor Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis Biosensors and Bioelectronics: X |
| title | Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis |
| title_full | Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis |
| title_fullStr | Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis |
| title_full_unstemmed | Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis |
| title_short | Discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using SERS mapping, assisted by multivariate spectral data analysis |
| title_sort | discrimination and quantification of methotrexate in the presence of its metabolites in patient serum using sers mapping assisted by multivariate spectral data analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2590137023000791 |
| work_keys_str_mv | AT goharsoufi discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT elodiedumont discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT yamangoksel discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT romanslipets discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT raheelaltafraja discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT kjeldschmiegelow discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT habibbagheri discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT anjaboisen discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis AT kingazor discriminationandquantificationofmethotrexateinthepresenceofitsmetabolitesinpatientserumusingsersmappingassistedbymultivariatespectraldataanalysis |